Loading data for CTMX — first visit, this takes a few seconds.

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS: CTMX · 实时价格 · USD

3.29

-0.06 (-1.79%)

收盘价： Sep 11, 2026, 3:59 PM

3.30

+0.30%

盘后: 7:59 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

-1.79% (1D)

买价	2.42
市值	717M
营收（TTM）	18.3M
净利润（TTM）	-82.7M
	2.14
	-0.57
	n/a
	-6.95
市净率（TTM）	2.37
市销率（TTM）	39.17
财报日期	Aug 7, 2025

卖价	4.16
成交量	2,249,974
20日均量	3,924,433
开盘价	3.38
前收盘价	3.35
日内区间	3.23 - 3.41
52周区间	1.90 - 8.21
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increa...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Oct 8, 2015

员工人数 69

交易所 NasdaqGS

股票代码 CTMX

官网 https://www.cytomx.com

公司完整简介

财务表现

2025年，CytomX Therapeutics的营收为76.2M，较上一年的138.1M下降-44.82%。净利润为-17.37M，下降-154.5%。

财务报表

财报意外

CytomX Therapeutics 已于 Aug 6, 2026 发布季度财报：

营收为 $1.42M 低于预期 $0, ， -92.40% 同比下滑.
每股收益为 -0.09 超出预期 0.01, ， -133.33% 同比下滑.

下次财报发布时间

CytomX Therapeutics, Inc. 的下次财报预计于 Aug 7, 2025, 收盘后。
分析师预计营收为 ... 升级

股价变动原因

新闻

1月前 · GuruFocus.com

CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...

Strong clinical progress and expanded Regeneron collaboration bolster CytomX's path forward despite revenue decline and safety considerations.

1月前 · MarketBeat

CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expa...

1月前 · Zacks

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2月前 · Zacks

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2月前 · Insider Monkey

Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?

CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its research collaboration with Regeneron to develop next-gen conditionally-act...

第 1 页，共 2 页

CytomX Therapeutics, Inc. (CTMX)